It was reported that over 79,000 people died of flu in the U.S. in the winter of 2017-2018, which was the highest death toll in four decades.1 It seems like the 2018-2019 flu season isn’t so bad.  How are sales of OTC drugs impacted by the severity of flu seasons?  Are there any opportunities for new products to capture market share?  How can companies ensure reliable supply of OTC medications based upon expected spikes in demand? 

Register for the webinar to learn the answers to these critical questions from industry experts.  We will review the current OTC remedies for cough, cold and allergy categories and discuss strategies to grow your share on shelf space with innovative dosage forms. 

Learning Objectives:

  • Learn the impact of flu season on OTC cough, cold and allergy products
  • Understand the trends in consumer demand for OTC remedies
  • Learn strategies to grow your market share with innovative dosage forms


 1. htttps://


Featured Speakers

Michael Kinishi

Principal, Product Management

Mike has 20+ years of FMCG market measurement expertise, and is a leader for IRI’s core content product management team developing data driven solutions for manufacturers and retailers.  He has broad expertise in data integration (point of sales, weather, e-commerce, illness incidence, economic indicators, etc.), product management, syndicated data analytics, project, process and program management. 

Humera Ahmad

Director of Product Development, Asia Pacific
Catalent Pharma Solutions

Humera Ahmad is Director of Product Development, Asia Pacific at Catalent Pharma Solutions. She is responsible for leading the Asia Pacific Product Development teams at Catalent Australia, China and Japan sites. Before joining Catalent, she worked at Probiotec Pharma (Australian Pharma Company) for nearly 10 years. She was the GM, Research and Development, responsible for creating the pipeline of new products (OTC/Prescription) as well as managing the QA, Regulatory and R&D groups.


Register now for this webinar